gilead yeztugo - Search News

News

HIV, CVS Health and Yeztugo

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV prevention breakthrough, at least for now. | CVS Health, the parent of PBM juggernaut CVS Caremark,

Zacks Investment Research on MSN · 15h

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

· 1d · on MSN

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.

From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Fierce Pharma14d

Amid excitement over Yeztugo, Gilead sees continued erosion of CAR-T sales

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while Tecartus saw a 14% drop-off to $92 million. In both cases, Gilead explained ...

14d

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

STAT1d

Pharmalittle: We’re reading about Gilead’s HIV drug, FDA speeding review of a rare disease drug, and more

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Seeking Alpha1mon

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for ...

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025 Jul. 14, 2025 9:30 AM ET Gilead Sciences, Inc. (GILD) ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results